期刊文献+

肝素诱导的血小板减少症研究现状 被引量:2

原文传递
导出
摘要 肝素诱导的血小板减少症(heparin-induced thromboeytopenia,HIT)是指使用肝素或低分子肝素后引起的血小板减少,伴或不伴有血栓形成。典型的表现为血小板计数降至150×10^9/L(国内标准应为100×10^9/L)以下或者比用药前最高数值减少50%以上,后者更有意义。约有20%~50%患者出现血栓的并发症。HIT的发生率各文献报道不一致,主要与使用肝素的剂量、剂型、疗程、给药途径以及血小板减少的数量定义不一致有关。从发生率讲,通常认为,
出处 《中华内科杂志》 CAS CSCD 北大核心 2009年第4期346-348,共3页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献18

  • 1Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost ,2005,94 : 132-135.
  • 2Warkentin TE, Maurer BT, Aster RH, et al. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med, 2007,356 : 2653 -2654.
  • 3Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin ( LMWH ) -induced heparin-induced thrombocytopenia ( HIT ). Thromb Haemost,2008,99:779-781.
  • 4Kelton JG, Warkentin TE. Heparin-induced thmrobocytopenia: a historical perspective. Blood, 2008, 112:2607-2616.
  • 5Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet- activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost, 2007,5 : 1666-1673.
  • 6Greinacher A, Gopinadhan M, Guenther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol,2006,26:2386-2393.
  • 7Warkentin TE, Greinacher A, Koster A, et al. Treatmem and prevention of heparin-indueed thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelinesaaa ( 8th Edition ). Chest, 2008,133 6 Suppl: 340S- 380S.
  • 8Warkentin TE, Kehon JG. Delayed-onset Heparin-induced thrombocytopenia and thrombosis. Ann Intern Med,2001,135: 502-506.
  • 9Lambert MP, Rauova L, Bailey M, et al. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryocytopoiesis: clinical and therapeutic implications. Blood, 2007, 110 : 1153- 1160.
  • 10Carrier M, Rodger MA, Fergusson D, et al. Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int,2008,73:213-219.

同被引文献24

  • 1季闽春,钱庆庆,杨耀芳.肝素诱导的血小板减少症的病因、诊断和治疗研究进展[J].中国临床药理学杂志,2007,23(6):461-465. 被引量:21
  • 2刘新,李爱.输血后紫癜[J].山东医药,2005,45(16):76-77. 被引量:2
  • 3赵彬,梅丹,李拥军,管珩.肝素诱导的血小板减少症[J].中国药师,2007,10(8):822-824. 被引量:12
  • 4Unteh B, Ahmad S, Jeske WP, et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of ISG. Thromb Res, 2002, 105 : 117-123.
  • 5Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126 : 311S-337S.
  • 6DeEugenio DL, Ruggiero N J, Thomson LJ, et al. Early-onset heparin- induced thrombocytopenia after a 165-day heparin-free interval:case report and review of the literature. Pharmacotherapy, 2005,25 : 615- 619.
  • 7Woedyard DN. An anesthesia provider' s perspective of heparin-- induced v thrombocytopenia. AANA J,2005,73:115-119.
  • 8Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin - induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence- Based Clinical Practice Guidelines [ J].Chest ,2012,141 ( 2 Suppl) : e496S-530S.
  • 9谢晓恬.《2009年版英国再生障碍性贫血诊断与治疗指南》要点归纳[J].中国循证医学杂志,2013,13(7):852-857.
  • 10史旭波,胡大一.警惕肝素诱导的血小板减少症[J].临床荟萃,2008,23(8):533-536. 被引量:28

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部